Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
NLSP NLS Pharmaceutics
- 1.9500
- -0.4300-18.07%
Close Dec 20 16:00 ET
- 1.9000
- -0.0500-2.56%
Post 20:01 ET
4.62MMarket Cap-0.29P/E (TTM)
2.2851High1.7800Low262.54KVolume2.2300Open2.3800Pre Close531.69KTurnover17.51%Turnover RatioLossP/E (Static)2.37MShares24.336052wk High-0.50P/B2.92MFloat Cap1.730052wk Low--Dividend TTM1.50MShs Float294.0000Historical High--Div YieldTTM21.22%Amplitude1.7300Historical Low2.0250Avg Price1Lot Size
About NLS Pharmaceutics Company
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.
Company Profile
SymbolNLSP
Company NameNLS Pharmaceutics
Listing DateJan 29, 2021
Issue Price4.15
Founded2015
CEOMr. Alexander Zwyer
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
AddressThe Circle 6
CityZurich
ProvinceZurich
CountrySwitzerland
Zip Code8058
Phone41-44-512-21-50
Websitehttp://www.nlspharma.com
Company Executives
- Name
- Position
- Salary
- Alexander Zwyer
- Chief Executive Officer and Director
- --
- George Apostol
- Chief Medical Officer and Global Head of Research and Development
- --
- Dr. Eric Konofal, M.D.
- Chief Scientific Officer
- --
- Elena Thyen-Pighin
- Chief Financial Officer and Head of Finance and Human Resources
- --
- Ronald Hafner
- Chairman of the Board
- --
- Gian-Marco Rinaldi
- Independent Director
- --
- Florence Allouche Aknin
- Independent Director
- --
- Claudio L. A. Bassetti
- Independent Director
- --
- Audrey Greenberg
- Independent Director
- --